Kermode Biotechnologies is a privately held American biotechnology company developing solutions for animal health, specifically targeting livestock viruses such as African Swine Fever Virus (ASFV) and Swine Flu. Its current pipeline comprises two products (therapeutic antibodies and immune-stimulating vaccine proteins) targetting ASFV. Kermode employs computational techniques to pinpoint vulnerable targets within viral structures, genetic compositions, and replication cycles and uses antibody discovery platforms to isolate potent therapeutic candidates, capable of safeguarding livestock from viral infections. This approach enables Kermode to identify robust antibody therapeutics and construct vaccine candidates that elicit durable in vivo responses.
Funding and financials
In May 2021, the company raised USD 1.2 million in venture funding backed by four investors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.